Chronic lymphocytic leukaemia trials in Poland

In Poland 36 Also abroad 308

36 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Where
Bialystok, Cracow, Gdansk, Katowice, Kielce, Lodz, Poznan, Skorzewo, Torun
Age
18 years and over
People
306 worldwide
Run by
Newave Pharmaceutical Inc
See details and how to joinNCT07342478 · EU 2026-525656-28-00
Phase 1Taking people
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Where
Gda?sk, Krakow, Wroc?aw
Age
18 years and over
People
332 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05091424
Phase 2Taking people
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Where
Bydgoszcz, Cracow, Katowice, Skorzewo, Wroclaw
Age
18 years and over
People
249 worldwide
Run by
Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Cracow, Gdansk, Katowice, Skorzewo
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 4Taking people
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Where
Brzozów, Bydgoszcz, Katowice
Age
18 years and over
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218341
Phase 2Taking people
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Where
Katowice, Krakow, Skorzewo, Warsaw
Age
18 years and over
People
100 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT07221500
Phase 4Taking people
Acalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients with Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
Where
Cracow, Poznan
Age
18 years and over
People
33 worldwide
Run by
AstraZeneca AB
See details and how to join2023-510147-37-00 · EU 2023-510147-37-00
Phase 2Taking people
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Where
Gdynia, Krakow, Opole, Warsaw, Wroclaw
Age
18 years and over
People
490 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00
Phase 3Taking people
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Where
Gdansk, Lodz, Torun, Warsaw, Wroclaw
Age
18 years and over
People
630 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00
Phase 2Taking people
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Where
Bydgoszcz, Lublin, Warsaw
Age
18 years to 130 years
People
80 worldwide
Run by
AstraZeneca
See details and how to joinNCT07024706 · EU 2024-518858-17-00
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Gliwice, Katowice, Krakow, Skorzewo (Poznan), Torun
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
Phase 3Taking people
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Where
Cracow, Gdansk, Gliwice, Katowice, Lublin, Olsztyn, Warsaw
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01
Phase 3Taking people
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
Where
Bydgoszcz, Gliwice, Katowice, Lodz, Torun, Warsaw
Age
18 years and over
People
746 worldwide
Run by
University Of Cologne
See details and how to join2023-510294-34-00 · EU 2023-510294-34-00
Phase 4Taking people
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Where
Cracow, Gdansk, Gliwice, Katowice, Lodz, Lublin, Warsaw, Wroclaw
Age
18 years and over
People
365 worldwide
Run by
Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
Phase 3Taking people
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Where
Katowice, Kielce, Krakow, Lublin, Skorzewo
Age
18 years and over
People
49 worldwide
Run by
Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00
Phase 3Taking people
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Where
Bydgoszcz, Cracow, Legnica, Olsztyn, Slupsk, Torun, Walbrzych
Age
18 years and over
People
386 worldwide
Run by
Grifols Therapeutics LLC
See details and how to joinNCT05645107 · EU 2022-502193-16-00
Phase 3Taking people
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Where
Brzozów, Cracow, Katowice, Lodz, Lublin, Wroclaw
Age
18 years and over
People
250 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00
Phase 3Taking people
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Where
Gdansk, Kielce, Lodz, Lublin, Olsztyn, Torun, Warsaw, Wroclaw
Age
18 years and over
People
500 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00
Phase 3Taking people
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Where
Brzozów, Cracow, Katowice, Lublin, Wroclaw
Age
18 years and over
People
500 worldwide
Run by
BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00
Phase 4Taking people
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Where
Krakow, Poznan
Age
18 years to 130 years
People
60 worldwide
Run by
AstraZeneca
See details and how to joinNCT06651970
Phase 2Taking people
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a Bcell Lymphoma-2 Inhibitor (BCL-2i) (DAYBreak CLL-201)
Where
Katowice, Krakow, Skorzewo, Warsaw
Age
18 years and over
People
45 worldwide
Run by
Nurix Therapeutics Inc.
See details and how to join2025-521088-10-00 · EU 2025-521088-10-00
Phase 1/2Taking people
A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Where
Biala Podlaska, Olsztyn
Age
18 years and over
People
60 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to join2024-515654-25-00 · EU 2024-515654-25-00
Phase 3Taking people
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Where
Biala Podlaska, Bydgoszcz, Cracow, Gdansk, Katowice, Lublin, Skorzewo, Wroclaw
Age
18 years and over
People
737 worldwide
Run by
Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00
Phase 1Taking people
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Where
Krakow, Lodz, Lublin, Skorzewo
Age
18 years and over
People
85 worldwide
Run by
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00
Phase 1Taking people
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Where
Cracow, Gdansk, Wroclaw
Age
18 years and over
People
54 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2022-501876-24-00 · EU 2022-501876-24-00